A forthcoming Department of Labor regulation will force pharmacy benefit managers to supply self-insured employers with granular medicine pricing data and direct compensation records. Set to take effect in July, the measure targets drugmaker rebates along with financial incentives that steer patients toward particular treatments. Meanwhile, the Treasury Department is advancing aggressive draft limitations on domestic investment within the Chinese biotech sector. Stakeholders continue to debate the broader fallout of the Treasury rule, especially concerning the scope of its licensing deal exemptions.
Key points
Self-insured employers will soon gain access to granular pharmaceutical pricing data to e…: Self-insured employers will soon gain access to granular pharmaceutical pricing data to evaluate pharmacy benefit manager compensation.
The impending July disclosure mandate targets industry practices that route patients to s…: The impending July disclosure mandate targets industry practices that route patients to specific drugs through manufacturer kickbacks.
Hello, everyone, and welcome to the middle of the week. Congratulations on making it this far. It is an accomplishment, after all. The next step is to … keep going. And why not? Just consider the alternatives. On that optimistic note, please join us for a needed cup or three of stimulation. Our choice today is coconut rum. Meanwhile, here are some items of interest to get you going. Have a wonderful day and do drop us a line when you hear something juicy. …
Ever since the U.S. Department of Treasury proposed to limit U.S. investment in the Chinese biotech industry last week, players across the U.S. are arguing over the significance of the restrictions, STAT explains. The main debate to date had been over whether restrictions are needed. Is it better to play offense by boosting domestic R&D or to play defense by trying to prevent Chinese biotechs from catching up? Is it even possible to slow China’s advance? Now, the debate has turned to the impact of the proposed rule, which is more aggressive than some anticipated.…
Federal regulators have granted licensed physicians and pharmacies temporary clearance to formulate six experimental compounds without facing penalties. The decision covers popular recovery treatments like BPC-157 and TB-500, marking a notable policy shift by the administration. This move proceeds despite warnings from agency researchers regarding the lack of data backing the safety or effectiveness of these substances.
A top Department of Health and Human Services official challenged conventional academic publishing models during a Wednesday address on restoring credibility to the scientific community. The former Great Barrington Declaration co-author argued that selective publication by journals damages institutional trust, while also linking pandemic-era restrictions to recent disease outbreaks. However, his assertions on lockdown impacts run contrary to consensus views held by public health experts.
Federal regulators are preparing an impending approval decision on the pharmaceutical company's emerging renal therapy. The heightened focus on safety issues comes as clinical specialists, market analysts, and investors assemble to evaluate key sector data.